Alaunos Therapeutics, Inc.
8-K
May 18, 2026
Key Highlights
- Strategic pivot from legacy cell therapy to high-growth metabolic disease market
- Early-stage development of ALN1003, an oral obesity and metabolic drug candidate
- Positive initial mouse studies demonstrating weight loss and improved insulin se...
Read Analysis
🤖 AI Generated